Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share
DNA.WS
DNA.WS was delisted on the 3rd of September, 2024.
71 hedge funds and large institutions have $40.9M invested in Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share in 2021 Q3 according to their latest regulatory filings, with 71 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCP
Diameter Capital Partners
New York
|
+$5.86M |
| 2 |
CH
CVI Holdings
Wilmington,
Delaware
|
+$5.33M |
| 3 |
ICM
Indaba Capital Management
San Francisco,
California
|
+$3.85M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$3.03M |
| 5 |
Morgan Stanley
New York
|
+$2.56M |
Top Sellers
DNA.WS Hedge Fund Activity: Q3 2021 in Review
71 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share (DNA.WS) for Q3 2021, worth a combined $40.9M.
Buyers outnumbered sellers: 71 funds opened new DNA.WS positions and 0 closed out — a net gain of 71 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Diameter Capital Partners, opening a new position worth an estimated $5.86M.
- 71 institutional investors held Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share (DNA.WS) as of Q3 2021, up from 0 in Q2 2021.
- Funds reported $40.9M of Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share stock for Q3 2021.
- 71 funds opened new Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share positions in Q3 2021 and 0 closed out, a net change of +71 holders.
- The largest Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share buyer in Q3 2021 was Diameter Capital Partners, an estimated $5.86M added.
Based on aggregated 13F filings for Q3 2021.